# Editas Medicine, Inc.: financial statements, quarterly

EDIT · Nasdaq · CIK 1650664 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/edit.md) · [Financials](/companies/edit/financials.md) · [Filings](/companies/edit/filings.md) · [Insiders](/companies/edit/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/edit/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.3](/filings/0001650664-24-000121.md) | [60.0 d](/filings/0001650664-25-000022.md) | [1.1](/filings/0001650664-25-000073.md) | [0.5](/filings/0001650664-25-000125.md) | [0.1](/filings/0001650664-25-000156.md) | [30.6 d](/filings/0001650664-26-000017.md) | [4.7](/filings/0001650664-26-000045.md) | [3.6](/filings/0001650664-26-000083.md) | [7.5](/filings/0001650664-25-000156.md) | [24.7 d](/filings/0001650664-26-000017.md) | [2.8](/filings/0001650664-26-000045.md) | [11.9](/filings/0001650664-26-000083.md) |
| Research and development | $m | [40.5](/filings/0001650664-24-000121.md) | [69.6 d](/filings/0001650664-25-000022.md) | [48.8](/filings/0001650664-25-000073.md) | [54.2](/filings/0001650664-25-000125.md) | [47.6](/filings/0001650664-25-000156.md) | [48.6 d](/filings/0001650664-26-000017.md) | [26.6](/filings/0001650664-26-000045.md) | [16.2](/filings/0001650664-26-000083.md) | [19.8](/filings/0001650664-25-000156.md) | [27.4 d](/filings/0001650664-26-000017.md) | [17.6](/filings/0001650664-26-000045.md) | [20.2](/filings/0001650664-26-000083.md) |
| Operating income | $m | [(50.2)](/filings/0001650664-24-000121.md) | [(24.0) d](/filings/0001650664-25-000022.md) | [(67.0)](/filings/0001650664-25-000073.md) | [(71.9)](/filings/0001650664-25-000125.md) | [(65.7)](/filings/0001650664-25-000156.md) | [(46.6) d](/filings/0001650664-26-000017.md) | [(76.2)](/filings/0001650664-26-000045.md) | [(51.5)](/filings/0001650664-26-000083.md) | [(24.5)](/filings/0001650664-25-000156.md) | [(7.8) d](/filings/0001650664-26-000017.md) | [(25.0)](/filings/0001650664-26-000045.md) | [(18.6)](/filings/0001650664-26-000083.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [2.1](/filings/0001650664-26-000045.md) | [0.0 d](/filings/0001650664-26-000083.md) | not reported | not reported | [5.0](/filings/0001650664-26-000045.md) | [0.0 d](/filings/0001650664-26-000083.md) |
| Net income | $m | [(45.0)](/filings/0001650664-24-000121.md) | [(18.9) d](/filings/0001650664-25-000022.md) | [(62.0)](/filings/0001650664-25-000156.md) | [(67.6)](/filings/0001650664-25-000156.md) | [(62.1)](/filings/0001650664-25-000156.md) | [(45.4) d](/filings/0001650664-26-000017.md) | [(76.1)](/filings/0001650664-26-000083.md) | [(53.2)](/filings/0001650664-26-000083.md) | [(25.1)](/filings/0001650664-25-000156.md) | [(5.6) d](/filings/0001650664-26-000017.md) | [(25.0)](/filings/0001650664-26-000083.md) | [(18.2)](/filings/0001650664-26-000083.md) |
| Diluted EPS | $ per share | [(0.55)](/filings/0001650664-24-000121.md) | not reported | [(0.76)](/filings/0001650664-25-000073.md) | [(0.82)](/filings/0001650664-25-000125.md) | [(0.75)](/filings/0001650664-25-000156.md) | not reported | [(0.92)](/filings/0001650664-26-000045.md) | [(0.63)](/filings/0001650664-26-000083.md) | [(0.28)](/filings/0001650664-25-000156.md) | not reported | [(0.26)](/filings/0001650664-26-000045.md) | [(0.15)](/filings/0001650664-26-000083.md) |
| Basic EPS | $ per share | [(0.55)](/filings/0001650664-24-000121.md) | not reported | [(0.76)](/filings/0001650664-25-000073.md) | [(0.82)](/filings/0001650664-25-000125.md) | [(0.75)](/filings/0001650664-25-000156.md) | not reported | [(0.92)](/filings/0001650664-26-000045.md) | [(0.63)](/filings/0001650664-26-000083.md) | [(0.28)](/filings/0001650664-25-000156.md) | not reported | [(0.26)](/filings/0001650664-26-000045.md) | [(0.15)](/filings/0001650664-26-000083.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [82.5](/filings/0001650664-24-000121.md) | [124](/filings/0001650664-25-000022.md) | [69.2](/filings/0001650664-25-000073.md) | [64.4](/filings/0001650664-25-000125.md) | [95.8](/filings/0001650664-25-000156.md) | [132](/filings/0001650664-26-000017.md) | [139](/filings/0001650664-26-000045.md) | [139](/filings/0001650664-26-000083.md) | [166](/filings/0001650664-25-000156.md) | [147](/filings/0001650664-26-000083.md) | [124](/filings/0001650664-26-000045.md) | [182](/filings/0001650664-26-000083.md) |
| Current assets | $m | [359](/filings/0001650664-23-000017.md) | [341](/filings/0001650664-25-000022.md) | [306](/filings/0001650664-24-000037.md) | [286](/filings/0001650664-24-000097.md) | [271](/filings/0001650664-24-000121.md) | [289](/filings/0001650664-26-000017.md) | [225](/filings/0001650664-25-000073.md) | [183](/filings/0001650664-25-000125.md) | [177](/filings/0001650664-25-000156.md) | [164](/filings/0001650664-26-000083.md) | [128](/filings/0001650664-26-000045.md) | [218](/filings/0001650664-26-000083.md) |
| Total assets | $m | [505](/filings/0001650664-23-000017.md) | [499](/filings/0001650664-25-000022.md) | [440](/filings/0001650664-24-000037.md) | [385](/filings/0001650664-24-000097.md) | [328](/filings/0001650664-24-000121.md) | [342](/filings/0001650664-26-000017.md) | [264](/filings/0001650664-25-000073.md) | [211](/filings/0001650664-25-000125.md) | [202](/filings/0001650664-25-000156.md) | [187](/filings/0001650664-26-000083.md) | [149](/filings/0001650664-26-000045.md) | [237](/filings/0001650664-26-000083.md) |
| Current liabilities | $m | [58.6](/filings/0001650664-23-000017.md) | [63.2](/filings/0001650664-25-000022.md) | [66.5](/filings/0001650664-24-000037.md) | [74.3](/filings/0001650664-24-000097.md) | [72.4](/filings/0001650664-24-000121.md) | [77.2](/filings/0001650664-26-000017.md) | [73.1](/filings/0001650664-25-000073.md) | [65.9](/filings/0001650664-25-000125.md) | [61.8](/filings/0001650664-25-000156.md) | [46.2](/filings/0001650664-26-000083.md) | [39.8](/filings/0001650664-26-000045.md) | [68.4](/filings/0001650664-26-000083.md) |
| Total liabilities | $m | [144](/filings/0001650664-23-000017.md) | [150](/filings/0001650664-25-000022.md) | [146](/filings/0001650664-24-000037.md) | [153](/filings/0001650664-24-000097.md) | [152](/filings/0001650664-24-000121.md) | [207](/filings/0001650664-26-000017.md) | [201](/filings/0001650664-25-000073.md) | [191](/filings/0001650664-25-000125.md) | [188](/filings/0001650664-25-000156.md) | [159](/filings/0001650664-26-000083.md) | [145](/filings/0001650664-26-000045.md) | [132](/filings/0001650664-26-000083.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001650664-25-000022.md) | not reported | not reported | not reported | [52.4](/filings/0001650664-26-000017.md) | [49.6](/filings/0001650664-25-000073.md) | [51.7](/filings/0001650664-25-000125.md) | [54.1](/filings/0001650664-25-000156.md) | [53.6](/filings/0001650664-26-000083.md) | [47.2](/filings/0001650664-26-000045.md) | [48.2](/filings/0001650664-26-000083.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001650664-25-000022.md) | not reported | not reported | not reported | [5.0](/filings/0001650664-26-000017.md) | [5.0](/filings/0001650664-25-000073.md) | [5.0](/filings/0001650664-25-000125.md) | [5.0](/filings/0001650664-25-000156.md) | [5.0](/filings/0001650664-26-000083.md) | [7.5](/filings/0001650664-26-000045.md) | [7.5](/filings/0001650664-26-000083.md) |
| Shareholders' equity | $m | [360](/filings/0001650664-24-000121.md) | [349](/filings/0001650664-26-000017.md) | [294](/filings/0001650664-25-000156.md) | [232](/filings/0001650664-25-000156.md) | [176](/filings/0001650664-25-000156.md) | [134](/filings/0001650664-26-000083.md) | [62.4](/filings/0001650664-26-000083.md) | [19.2](/filings/0001650664-26-000083.md) | [13.5](/filings/0001650664-25-000156.md) | [27.3](/filings/0001650664-26-000083.md) | [4.4](/filings/0001650664-26-000083.md) | [105](/filings/0001650664-26-000083.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(35.5) d](/filings/0001650664-24-000121.md) | [(22.2) d](/filings/0001650664-25-000022.md) | [(49.9)](/filings/0001650664-25-000073.md) | [(57.1) d](/filings/0001650664-25-000125.md) | [(52.6) d](/filings/0001650664-25-000156.md) | [(50.8) d](/filings/0001650664-26-000017.md) | [(47.8)](/filings/0001650664-26-000045.md) | [(50.2) d](/filings/0001650664-26-000083.md) | [(30.8) d](/filings/0001650664-25-000156.md) | [(36.4) d](/filings/0001650664-26-000017.md) | [(23.1)](/filings/0001650664-26-000045.md) | [(29.6) d](/filings/0001650664-26-000083.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001650664-24-000121.md) | [1.3 d](/filings/0001650664-25-000022.md) | [1.9](/filings/0001650664-25-000073.md) | [3.5 d](/filings/0001650664-25-000125.md) | [2.9 d](/filings/0001650664-25-000156.md) | [0.5 d](/filings/0001650664-26-000017.md) | [0.1](/filings/0001650664-26-000045.md) | [0.0 d](/filings/0001650664-26-000083.md) | [0.4 d](/filings/0001650664-25-000156.md) | [0.1 d](/filings/0001650664-26-000017.md) | [0.1](/filings/0001650664-26-000045.md) | [0.1 d](/filings/0001650664-26-000083.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [68.7](/filings/0001650664-23-000017.md) | [68.9](/filings/0001650664-24-000037.md) | [71.4](/filings/0001650664-24-000097.md) | [81.6](/filings/0001650664-24-000121.md) | [81.9](/filings/0001650664-25-000073.md) | [82.3](/filings/0001650664-25-000125.md) | [82.5](/filings/0001650664-25-000156.md) | [83.1](/filings/0001650664-26-000045.md) | [84.4](/filings/0001650664-26-000083.md) | [90.1](/filings/0001650664-25-000156.md) | [97.9](/filings/0001650664-26-000045.md) | [119](/filings/0001650664-26-000083.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 153,580,035 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001650664-26-000083.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.